Due to the fact that cancer cells often have multiple genetic aberrations leading to differences in drug sensitivity43,44 and having observed a significant LMP-induced reduction of RAS oncoprotein expression, we then tested the efficacy of VP on a panel of seven distinct HCC cell lines differing in their RAS status (wild-type and mutated) and mutant B-RAF (SK-Hep-1 cell line). The gene discussed is BRAF; the disease is hepatocellular carcinoma.